The present invention relates to processes for preparing antioxidant liquid extracts and compositions and uses of such antioxidant liquid extracts and compositions. Also provided are novel antioxidant liquid extracts and compositions comprising astaxanthin. The antioxidant liquid extracts and compositions inter alia exhibit high antioxidant activity.

[PROBLEM] To provide a coenzyme Q production accelerator that allows increasing an intracellular coenzyme Q level.

[SOLUTION] The present invention is a coenzyme Q production accelerator containing nicotinamide mononucleotide as an active ingredient.

The present invention relates to β-L-aspartyl-L-arginine for use as an anti-inflammatory agent on the skin as well as the cosmetic use of β-L-aspartyl-L-arginine on mature skin. It particular, the β-L-aspartyl-L-arginine provides an antioxidative effect and/or improves mitochondrial function in senescent skin cells, in particular senescent fibroblasts, and/or restores firmness of the skin. Furthermore, the invention also provides a cosmetic method for the treatment of mature skin. The present invention also relates to β-L-aspartyl-L-arginine for use in a therapeutic method for the treatment of damaged mature skin. In particular, the β-L-aspartyl-L-arginine is provided for use in a therapeutic method to promote wound healing.

The present invention relates to β-L-aspartyl-L-arginine for use as an anti-inflammatory agent on the skin as well as the cosmetic use of β-L-aspartyl-L-arginine on mature skin. It particular, the β-L-aspartyl-L-arginine provides an antioxidative effect and/or improves mitochondrial function in senescent skin cells, in particular senescent fibroblasts, and/or restores firmness of the skin. Furthermore, the invention also provides a cosmetic method for the treatment of mature skin. The present invention also relates to β-L-aspartyl-L-arginine for use in a therapeutic method for the treatment of damaged mature skin. In particular, the β-L-aspartyl-L-arginine is provided for use in a therapeutic method to promote wound healing.

This disclosure relates to an enzymatic method including the steps of adding water to a reactor vessel with gentle mixing and minimal heating, adding osmotic protectant solution, adding plant material to the reactor, adding cell wall degrading enzymes at 0.1% wt/wt based on plant weight, heating the reactor now filled with plant material, osmotic protectant solution and enzyme blend solution to 30° C.-35° C., adding the enzyme mixture to the reactor and starting the timer for up to 2 hours, adding bulk density enhancer, further mixing the product, and drying the finished product containing protoplasts. The protoplast containing product may be provided in a dietary supplement for human use having antioxidant and anti-inflammatory properties.

This disclosure relates to an enzymatic method including the steps of adding water to a reactor vessel with gentle mixing and minimal heating, adding osmotic protectant solution, adding plant material to the reactor, adding cell wall degrading enzymes at 0.1% wt/wt based on plant weight, heating the reactor now filled with plant material, osmotic protectant solution and enzyme blend solution to 30° C.-35° C., adding the enzyme mixture to the reactor and starting the timer for up to 2 hours, adding bulk density enhancer, further mixing the product, and drying the finished product containing protoplasts. The protoplast containing product may be provided in a dietary supplement for human use having antioxidant and anti-inflammatory properties.

The present invention relates to a pharmaceutical composition, which is characterized in that the composition comprises an effective amount of proanthocyanidin, the monomer units of the proanthocyanidin have the chemical formula of formula (I), and a pharmaceutically acceptable carrier or salt; wherein the proanthocyanidin is a polymeric proathocyanidin with a degree of polymerization ranging from 50-65. It has good antioxidant stress and can be used to treat or prevent brain diseases and aging-related diseases caused by excessive production of ROS, or to prevent and treat aging. It can also be used for the treatment and prevention of liver disease, tumor, sarcopenia and other diseases.

The present invention relates to a pharmaceutical composition, which is characterized in that the composition comprises an effective amount of proanthocyanidin, the monomer units of the proanthocyanidin have the chemical formula of formula (I), and a pharmaceutically acceptable carrier or salt; wherein the proanthocyanidin is a polymeric proathocyanidin with a degree of polymerization ranging from 50-65. It has good antioxidant stress and can be used to treat or prevent brain diseases and aging-related diseases caused by excessive production of ROS, or to prevent and treat aging. It can also be used for the treatment and prevention of liver disease, tumor, sarcopenia and other diseases.

Zeolites for extraction of heavy metals are given enhanced purification in a first method stage and further processed in a second method stage to form liquid and solid phases including swollen clinoptilolite fragments ranging from 200 to 2000 Daltons and formed as liposomes and usable to substantially reduce heavy metal ppm burdens for purposes of safe ingestion by mammals and reduction of heavy metal contaminants of gut, vascular and lymphatic systems of a mammalian host.

Zeolites for extraction of heavy metals are given enhanced purification in a first method stage and further processed in a second method stage to form liquid and solid phases including swollen clinoptilolite fragments ranging from 200 to 2000 Daltons and formed as liposomes and usable to substantially reduce heavy metal ppm burdens for purposes of safe ingestion by mammals and reduction of heavy metal contaminants of gut, vascular and lymphatic systems of a mammalian host.